PRINCETON, N.J. , May 22, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its initial public offering of 9,166,667 shares of...

PRINCETON, N.J. , June 18, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , the Company's Chief Executive...

Expands Patent Portfolio for its Contraceptive Patch, Twirla™...

PRINCETON, N.J. , June 30, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced it has been added to the Russell Microcap Index....

Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System...

Company on Track With Initiation of Confirmatory Phase 3 Clinical Trial of Twirla(TM) in Third Quarter of 2014...

PRINCETON, N.J. , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Mr....

Twirla (AG200-15) is a Novel Low-Dose Combined Hormonal Contraceptive Patch Designed Using the Company's Proprietary Transdermal Skinfusion ® Technology Confirmatory SECURE Study To Build Upon Data From Previous Phase 3 Studies in Support of the Company's New Drug Application to the U.S....